Aurobindo Pharma Stock Rises on Production Restart

  Published 1 year ago

Shares of India's Aurobindo Pharma rise 2.4% as Lyfius Pharma restarts Kakinada production, despite a 15% YTD drop.

  • Restarting Kakinada facility boosts shares; analysts rate stock 'buy' with 1370 rupees median target.
  • Stock up 2.4% on production resumption despite year, to, date decline of about 15%.
  • LSEG data shows a positive outlook for Aurobindo Pharma amid operational recovery.

You might like these

TRAI Q1 FY26 Telecom Report

Solara Pharma Turns Profitable in Q1

Chandan Verma Appointed CFO at HSRC Infra Services

Titan Intech Joins MIC for Mini-LED Tech

Bansal Wire Surges on DAM Buy Rating, Targets 24% Gains

ArisInfra Turns Profitable in FY25

JSW Steel FY25: Mixed Results & Outlook

News that matters the most ⚡